Evaluation of hypoglycemic therapeutics and nutritional supplementation for type 2 diabetes mellitus management: An insight on molecular approaches
- 4 February 2022
- journal article
- review article
- Published by Springer Nature in Biotechnology Letters
- Vol. 44 (2) , 203-238
Abstract
Objective This review aims to summarize the current management of type 2 diabetes principles, including oral hypoglycemic agents, types of insulin administration, diet maintenance, and various molecular approaches. Methods A literature search was conducted in different databases such as Scopus, ScienceDirect, Google Scholar, and Web of Science by using the following keywords: type-2 diabetes mellitus (T2DM), first-line and second-line treatment, oral hypoglycemic agents, insulin administration, diet/nutritional therapy, gene and stem cell therapy, and diabetic complications. Results The first-line treatment of T2DM includes administering oral hypoglycemic agents (OHAs) and second-line treatment by insulin therapy and some OHAs like Sulfonylurea’s (SU). The oral hypoglycemic or oral antidiabetic drugs have the function of lowering glucose in the blood. Insulin therapy is recommended for people with A1C levels > 7.0, and insulin administration is evolved drastically from the syringe, pump, pen, inhalation, insulin jet, and patch. The use of OHAs and insulin therapy during glycemic control has a severe effect on weight gain and other side effects. Hence, diet maintenance (macro and micronutrients) and nutritional therapy guidelines were also reviewed/recommended for safe T2DM management. Besides, the recent progress in molecular approaches that focuses on identifying new targets for T2DM (i.e.) consisting of gene therapy, stem cell therapy, and the modulation of insulin signaling pathways for the regulation of glucose storage and uptake also discussed. Conclusion The analysis of all these key factors is necessary to develop a potential agent to cure T2DM and suggest that a combination of therapies will pave the way for advanced management of T2DM.Keywords
This publication has 215 references indexed in Scilit:
- Role of self-care in management of diabetes mellitusJournal of Diabetes & Metabolic Disorders, 2013
- Sustained Exendin-4 Secretion through Gene Therapy Targeting Salivary Glands in Two Different Rodent Models of Obesity/Type 2 DiabetesPLOS ONE, 2012
- Elevated NF-κB Activation Is Conserved in Human Myocytes Cultured From Obese Type 2 Diabetic Patients and Attenuated by AMP-Activated Protein KinaseDiabetes, 2011
- Type 2 Diabetes Is Associated with Altered NF-κB DNA Binding Activity, JNK Phosphorylation, and AMPK Phosphorylation in Skeletal Muscle after LPSPLOS ONE, 2011
- AMP-activated protein kinase inhibits NF-κB signaling and inflammation: impact on healthspan and lifespanJournal of Molecular Medicine, 2011
- The OmniPod Insulin Management System: the latest innovation in insulin pump therapyDiabetes Therapy, 2010
- Insulin Patch Pumps: Their Development and Future in Closed-Loop SystemsDiabetes Technology & Therapeutics, 2010
- The Protein Kinase IKKɛ Regulates Energy Balance in Obese MiceCell, 2009
- Leptin Deficiency and Beta-Cell Dysfunction Underlie Type 2 Diabetes in Compound Akt Knockout MiceMolecular and Cellular Biology, 2009
- Thiazolidinedione use is associated with better survival in hemodialysis patients with non-insulin dependent diabetesKidney International, 2009